Generation Bio (NASDAQ:GBIO) Rating Increased to Hold at Zacks Research

Generation Bio (NASDAQ:GBIO) was upgraded by Zacks Research to a “hold” rating in a research report issued on Monday,Zacks.com reports.

GBIO has been the subject of several other reports. Citigroup reissued a “market perform” rating on shares of Generation Bio in a research note on Wednesday, December 17th. Needham & Company LLC reissued a “buy” rating and issued a $15.00 price objective on shares of Generation Bio in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Generation Bio in a report on Thursday, January 22nd. Jefferies Financial Group cut Generation Bio from a “buy” rating to a “hold” rating and reduced their price target for the stock from $11.00 to $5.00 in a report on Tuesday, December 16th. Finally, Wedbush set a $5.50 price objective on Generation Bio and gave the company an “outperform” rating in a research report on Tuesday, December 16th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.88.

Generation Bio Price Performance

Shares of NASDAQ:GBIO opened at $5.67 on Monday. The company’s 50-day moving average price is $5.44 and its two-hundred day moving average price is $5.55. Generation Bio has a one year low of $3.00 and a one year high of $9.03. The stock has a market capitalization of $38.20 million, a PE ratio of -0.61 and a beta of 2.05.

Generation Bio (NASDAQ:GBIO) last released its earnings results on Wednesday, November 5th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.18) by $2.36. Generation Bio had a negative return on equity of 94.82% and a negative net margin of 410.13%.The business had revenue of $1.59 million for the quarter, compared to the consensus estimate of $0.66 million. On average, analysts anticipate that Generation Bio will post -1.75 earnings per share for the current fiscal year.

Institutional Trading of Generation Bio

Several institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC bought a new position in Generation Bio during the 1st quarter worth $36,000. Acadian Asset Management LLC increased its position in Generation Bio by 54.3% during the first quarter. Acadian Asset Management LLC now owns 1,159,135 shares of the company’s stock worth $468,000 after acquiring an additional 407,843 shares during the period. Y Intercept Hong Kong Ltd bought a new position in Generation Bio during the second quarter worth about $47,000. Marshall Wace LLP acquired a new stake in Generation Bio in the 2nd quarter worth about $37,000. Finally, Militia Capital Partners LP bought a new stake in Generation Bio in the 2nd quarter valued at about $174,000. 95.22% of the stock is currently owned by institutional investors.

About Generation Bio

Generation Bio, Inc (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors.

The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation.